Clinical trials: Malignant Pleural Neoplasm
Relapsed Malignant Mesothelioma
A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
The purpose of this study is to evaluate rising dose levels of VS-5584 administered in combination with a fixed dose of VS-6063 in subjects with relapsed malignant mesothelioma to determine a recommended Phase 2 dose (RP2D) for…
- Trial name
- NCT02372227
- Testing
- VS-5584 and VS-6063
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 21 people
- Sponsor
- Verastem, Inc.
Non-Small Cell Lung Cancer
A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab…
- Trial name
- NCT00343291
- Testing
- Cetuximab, Bevacizumab, Paclitaxel
- Where
- 43 sites in United States
- Volunteers
- 121 people
- Sponsor
- Eli Lilly and Company
Malignant Pleural Mesothelioma
A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma
Mesothelioma is a relatively rare cancer which is becoming more common. It can affect one of two areas; the pleura (the lining of the lung) or the peritoneum (the lining of the abdomen).
- Trial name
- MESO-02 (NCT01353482)
- Testing
- Cisplatin, Pemetrexed, Vorinostat
- Sponsor
- University College, London
Lung Cancer, Gastro-Intestinal Cancer
Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program
This study evaluates physical performance in cancer outpatients during a multimodal therapy. Half of the patients will receive physical exercise und nutrition program in combination with a specially formulated whey protein…
- Conditions
- Lung Cancer, Gastro-Intestinal Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT02585362
- Testing
- physical exercise, nutrition counseling, whey protein supplement
- Where
- Switzerland
- Volunteers
- 52 people
- Sponsor
- Kantonsspital Winterthur KSW
Mesothelioma, Malignant, Mesothelioma, Malignant Pleural
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
This study is a single-arm, open-lable, single-center phase II clinical trial for patients with advanced or metastatic pleural mesothelioma.
- Conditions
- Mesothelioma, Malignant, Mesothelioma, Malignant Pleural, Mesothelioma Malignant Advanced
- Trial name
- NCT05188859
- Testing
- Sintilimab+Anlotinib+Pemetrexed+Cisplatin
- Where
- 2 sites in China
- Volunteers
- 29 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lung Cancer, Non-small Cell Lung Cancer (NSCLC)
Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to: Find out if the study drugs Afatinib and Dasatinib can be safely given together to patients with lung cancer Learn how these two drugs work in cancer cells when they are combined Learn more about…
- Trial name
- NCT01999985
- Testing
- Dasatinib - 1A, Afatinib - 1A, Dasatinib - 1B
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lung Cancer
Study of Weekly Paclitaxel, Carboplatin and Irinotecan to Treat Lung Cancer
Evaluate the efficacy and toxicity of the weekly combination chemotherapy of Paclitaxel, Carboplatin and Irinotecan in Stage IIIb and IV NSCLC with malignant pleural effusion
- Trial name
- NCT00465907
- Testing
- Paclitaxel, Carboplatin and Irinotecan
- Where
- Singapore
- Volunteers
- 7 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Malignant Pleural Mesothelioma
Effect of Expression of CD74 and VEGF on Outcome of Treatment in Patients With Malignant Pleural Mesothelioma
This is a prospective study evaluating the effect of expression of CD74 and VEGF on outcome of treatment in patients with malignant pleural mesothelioma receiving Pemetrexed/Platinum protocol.
- Trial name
- NCT02761863
- Testing
- CD 74, VEGF detection
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
Malignant Pleural Mesothelioma, Unresectable Malignant Neoplasm
Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)
Meso-Immune is a retrospective study to assess the efficacy and safety of the combination of Nivolumab and Ipilimumab used in first-line treatment of adult patients with unresectable Malignant Pleural Mesothelioma (MPM).
- Trial name
- MESO-IMMUNE (NCT05308966)
- Testing
- Data collection
- Where
- 63 sites in France
- Volunteers
- 204 people
- Sponsor
- Groupe Francais De Pneumo-Cancerologie
Colorectal Cancer Not MSI-H or MMR-deficient, GIST
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been determined (phase I trial).
- Conditions
- Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer
- Trial name
- REGOMUNE (NCT03475953)
- Testing
- Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib
- Where
- 7 sites in France
- Volunteers
- 747 people
- Sponsor
- Institut Bergonié
Malignant Mesothelioma
Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00017186
- Testing
- epirubicin hydrochloride, gemcitabine hydrochloride
- Where
- 24 sites in United States
- Volunteers
- 69 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pleural Effusion, Malignant
Multicentre Study Comparing Indwelling Pleural Catheter With Talc Pleurodesis for Malignant Pleural Effusion Management
Malignant pleural effusion (MPE) accounts for 50% of all pleural effusions and affects about 300,000 patients annually (UK and USA).
- Trial name
- NCT02045121
- Testing
- Indwelling Pleural Catheter, Talc Pleurodesis
- Where
- Singapore
- Volunteers
- 160 people
- Sponsor
- National University Hospital, Singapore
Malignant Pleural Mesothelioma, Diagnoses Disease
Real World Study of MPM in China
Malignant pleural mesothelioma (MPM) is a highly aggressive tumor with atypical clinical manifestations. Most patients with MPM are at an advanced stage at the time of diagnosis, and only a few patients can be cured by radical…
- Conditions
- Malignant Pleural Mesothelioma, Diagnoses Disease, Treatments, Prognosis
- Trial name
- NCT05042557
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Chinese Academy of Medical Sciences
Pleural Malignant Mesothelioma
Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma
This study is being conducted to evaluate the overall safety and effectiveness of an investigational drug, GC1008, in patients with mesothelioma. An investigational drug is one that has not been approved by the FDA.
- Trial name
- NCT01112293
- Testing
- GC1008
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Pleural Effusion, Malignant
The Added Value of CT Scanning in Patients With an Unilateral Pleural Effusion
To investigate the diagnostic power of computed tomography for discriminating malignant from nonmalignant causes to pleural effusions in consecutive patients with no malignant cells found at a cytological examination and a chest…
- Trial name
- NCT03270215
- Testing
- Computed tomography
- Where
- Denmark
- Volunteers
- 232 people
- Sponsor
- Naestved Hospital
Malignant Pleural Effusion, Pleural Neoplasms
OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.
This study will monitor and evaluate patient and personnel safety and toxicity during the implementation and evaluation of Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) directed treatment.
- Conditions
- Malignant Pleural Effusion, Pleural Neoplasms, Quality of Life, Chemotherapy Effect
- Trial name
- NCT06421610
- Testing
- PITAC
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Odense University Hospital
Breast Cancer, Colorectal Cancer
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Vaccines made from a patient's tumor tissue may make the body build an immune response to kill tumor…
- Conditions
- Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00002475
- Testing
- allogeneic tumor cell vaccine, autologous tumor cell vaccine, recombinant interferon alfa
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- St. Vincent Medical Center - Los Angeles
Pleural Malignant Mesothelioma
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
This phase I/II trial studies the side effects and how well pembrolizumab with or without anetumab ravtansine works in treating patients with mesothelin-positive pleural mesothelioma.
- Trial name
- NCT03126630
- Testing
- Anetumab Ravtansine, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 33 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Pleural Mesothelioma, Non-Small Cell Lung Cancer
A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma
This is an open-label, multicenter, phase 1/2 study of BBI608 in combination with pemetrexed and cisplatin chemotherapy as a 1st line treatment for Malignant Pleural Mesothelioma (MPM).
- Trial name
- NCT02347917
- Testing
- BBI608, Pemetrexed, Cisplatin
- Where
- 2 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Mesothelioma, Malignant
......SMARTEST Trial......
The SMARTEST trial is a phase II non-blinded randomized trial designed to evaluate the benefit of low dose cyclophosphamide in sequential combination with sub-ablative radiation (Arm A) versus sub-ablative radiation alone (Arm B)…
- Trial name
- NCT05380713
- Testing
- Cyclophosphamide, Tremelimumab, Durvalumab
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto